Obesity-related hypertension

被引:0
|
作者
Adamczak, Marcin [1 ]
Gojowy, Damian [1 ]
Wiecek, Andrzej [1 ]
机构
[1] Slaskiego Uniwersytetu Med Katowicach, Katedra & Klin Nefrol Transplantol & Chorob Wewne, Ul Francuska 20-24, PL-40027 Katowice, Poland
来源
ARTERIAL HYPERTENSION | 2014年 / 18卷 / 04期
关键词
hypertension; obesity; obesity-related hypertension; antihypertensive treatment in obese patients;
D O I
暂无
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
For nearly a century, it is known that hypertension and obesity often coexist. The pathogenetic mechanisms leading to hypertension in obese patients are complex. The most important are: sympathetic nervous system overactivation, increased sodium reabsorption in the renal tubules leading to hypervolemia, insulin resistance, stimulation of the renin-angiotensin-aldosterone system and disturbances of the adipokines secretion. The goal of antihypertensive therapy in obese subjects is to obtain blood pressure below 140/90 mm Hg. Basic methods of antihypertension treatment in obese patients is to reduce body fat mass by calorie restrictive diet and increased physical activity. Recommended for advanced obesity bariatric surgery may also exert an antihypertensive effect. In pharmacotherapy of hypertension in obese patients preferentially are angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists. In order to obtain the target of blood pressure in these patients usually it is necessary to use two or more antihypertensive drugs.
引用
收藏
页码:224 / 236
页数:13
相关论文
共 50 条
  • [31] Adiponectin replenishment ameliorates obesity-related hypertension
    Ohashi, Koji
    Kihara, Shinji
    Ouchi, Noriyuki
    Kumada, Masahiro
    Fujita, Koichi
    Hiuge, Aki
    Hibuse, Toshiyuki
    Ryo, Miwa
    Nishizawa, Hitoshi
    Maeda, Norikazu
    Maeda, Kazuhisa
    Shibata, Rei
    Walsh, Kenneth
    Funahashi, Tohru
    Shimomura, Iichiro
    [J]. HYPERTENSION, 2006, 47 (06) : 1108 - 1116
  • [32] Hydralazine as antihypertensive therapy in obesity-related hypertension
    J F Carroll
    J W King
    J S Cohen
    [J]. International Journal of Obesity, 2004, 28 : 384 - 390
  • [33] Effect of diabetes and hypertension on obesity-related mortality
    Livingston, EH
    Ko, CY
    [J]. SURGERY, 2005, 137 (01) : 16 - 25
  • [34] Recent developments in the treatment of obesity-related hypertension
    Pischon, T
    Sharma, AM
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2002, 11 (05): : 497 - 502
  • [35] Treatment of Obesity-Related Hypertension in Children and Adolescents
    Susan M. Halbach
    Joseph Flynn
    [J]. Current Hypertension Reports, 2013, 15 : 224 - 231
  • [36] Highlights of mechanisms and treatment of obesity-related hypertension
    Shams, Elham
    Kamalumpundi, Vijayvardhan
    Peterson, Joshua
    Gismondi, Ronaldo Altenburg
    Oigman, Wille
    de Gusmao Correia, Marcelo Lima
    [J]. JOURNAL OF HUMAN HYPERTENSION, 2022, 36 (09) : 785 - 793
  • [37] THE ZUCKER RAT AS A MODEL OF OBESITY-RELATED HYPERTENSION
    KURTZ, TW
    MORRIS, RC
    PERSHADSINGH, HA
    [J]. HYPERTENSION, 1988, 12 (03) : 354 - 354
  • [38] Correlation between obesity-related indices and hypertension
    Zhao, Guangyi
    Zhou, Zhiyi
    [J]. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (08): : 3842 - 3850
  • [39] Uric acid level is one of the predictors of hypertension, obesity and obesity-related hypertension
    Masuo, K
    Mikami, H
    Ogihara, T
    Tuck, ML
    [J]. HYPERTENSION, 2002, 40 (03) : 385 - 385
  • [40] Pathophysiological role of leptin in obesity-related hypertension
    Aizawa-Abe, M
    Ogawa, Y
    Masuzaki, H
    Ebihara, K
    Satoh, N
    Iwai, H
    Matsuoka, N
    Hayashi, T
    Hosoda, K
    Inoue, G
    Yoshimasa, Y
    Nakao, K
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (09): : 1243 - 1252